Phaseline

Targets › CHRM1

CHRM1 (Muscarinic acetylcholine receptor M1): drug programs, companies and trials

17 programs from 16 companies in 47 trials: 24 Phase 3, 12 Phase 2, 8 Phase 1, 3 Phase 4; Psychiatry, Ophthalmology, Neurology; next expected readout Dec 2026.

The muscarinic acetylcholine receptor mediates various cellular responses, including inhibition of adenylate cyclase, breakdown of phosphoinositides and modulation of potassium channels through the action of G proteins. Primary transducing effect is Pi turnover. (UniProt, P11229)

Open in Phaseline: the race on CHRM1, likelihood bands and readouts

Programs

CompanyDrugTargetsHighest phaseConditionsNext expected readout
Southern College of OptometryPilocarpine
Muscarinic acetylcholine receptor M3 agonist; Muscarinic acetylcholine receptor M1 agonist
CHRM3, CHRM1Phase 4Presbyopia–
Hospital Sirio-LibanesBiperiden Hydrochloride
Muscarinic acetylcholine receptor M1 antagonist
CHRM1Phase 3Brain Injury Traumatic ModerateDec 2026
Bristol-Myers SquibbXanomeline
Muscarinic acetylcholine receptor M4 agonist; Muscarinic acetylcholine receptor M1 agonist
CHRM4, CHRM1Phase 3Alzheimer Disease; Alzheimer's Disease; Healthy Volunteers; SCHIZOPHRENIA 1 (Disorder)Mar 2027
Ocus Innovation IrelandAtropine
Muscarinic acetylcholine receptor M3 antagonist; Muscarinic acetylcholine receptor M1 antagonist; Muscarinic acetylcholine receptor M2 antagonist
CHRM3, CHRM1, CHRM2Phase 3MyopiaDec 2027
Oslo University HospitalBuscopan 20 MG/ML Injectable Solution
Anticholinergic agent that reduces smooth muscle spasms
CHRM1, CHRM3Phase 3Labor ComplicationDec 2027
Montefiore Medical CenterPilocarpine
Muscarinic acetylcholine receptor M3 agonist; Muscarinic acetylcholine receptor M1 agonist
CHRM3, CHRM1Phase 3GlaucomaJun 2028
Sherief Abd-Elsalamorphenadrine
Anticholinergic drug with CNS and peripheral activity; used for muscle spasms and pain
CHRM1, CHRM2, CHRM3Phase 3Liver CirrhosisDec 2028
Bristol-Myers SquibbXanomeline (BMS-986519)
Muscarinic acetylcholine receptor M4 agonist; Muscarinic acetylcholine receptor M1 agonist
CHRM4, CHRM1Phase 3SchizophreniaMar 2030
Zhaoke (Guangzhou) Ophthalmology PharmaceuticalAtropine
Muscarinic acetylcholine receptor M3 antagonist; Muscarinic acetylcholine receptor M1 antagonist; Muscarinic acetylcholine receptor M2 antagonist
CHRM3, CHRM1, CHRM2Phase 3Myopia; Achalasia; Progressive Myopia; Focus on Axial Length …–
Belfast Health and Social Care TrustAtropine Sulfate
Muscarinic acetylcholine receptor M3 antagonist; Muscarinic acetylcholine receptor M1 antagonist; Muscarinic acetylcholine receptor M2 antagonist
CHRM3, CHRM1, CHRM2Phase 2MyopiaFeb 2027
NovartisGlycopyrronium bromide
Muscarinic acetylcholine receptor M3 antagonist; Muscarinic acetylcholine receptor M1 antagonist
CHRM3, CHRM1Phase 2Asthma; Post-Dural Puncture HeadacheJul 2027
ACADIA PharmaceuticalsACP-211
Muscarinic M1 receptor positive allosteric modulator
CHRM1Phase 2Major Depressive Disorder (MDD)Aug 2027
AstraZenecaGlycopyrronium
Muscarinic acetylcholine receptor M3 antagonist; Muscarinic acetylcholine receptor M1 antagonist; Muscarinic acetylcholine receptor inhibitor
CHRM3, CHRM1, CHRM4, CHRM2, CHRM5Phase 2AsthmaMay 2029
Anavex Life SciencesANAVEX3-71
Dual SIGMAR1 receptor agonist and M1 positive allosteric modulator
SIGMAR1, CHRM1Phase 2Schizophrenia–
Brigham and Women's HospitalAtomoxetine-plus-oxybutynin (AtoOxy)
Norepinephrine reuptake inhibitor combined with muscarinic antagonist to activate pharynge
SLC6A2, CHRM1Phase 1Obstructive Sleep ApneaSep 2028
Joshua A. Lile, Ph.D.Cobenfy
M1 muscarinic receptor agonist and 5-HT1A receptor partial agonist
HTR1A, CHRM1Phase 1Cocaine Use Disorder (CUD)Jun 2032
NSC-TherapeuticsNSC001
M1 muscarinic receptor agonist
CHRM1Phase 1Alzheimer Disease–

Conditions

Myopia (17) Alzheimer Disease (4) Alzheimer's Disease (3) Healthy Volunteers (2) Progressive Myopia (2) Myopia, Progressive (2) Schizophrenia (2) Asthma (2) SCHIZOPHRENIA 1 (Disorder) (1) Achalasia (1) Focus on Axial Length (1) Epiphora (1)

Modalities

small molecule (16)

Companies

Bristol-Myers Squibb (2) Zhaoke (Guangzhou) Ophthalmology Pharmaceutical (1) Anavex Life Sciences (1) Montefiore Medical Center (1) Ocus Innovation Ireland (1) Belfast Health and Social Care Trust (1) Oslo University Hospital (1) Joshua A. Lile, Ph.D. (1) Brigham and Women's Hospital (1) Southern College of Optometry (1) Hospital Sirio-Libanes (1) Novartis (1) AstraZeneca (1) ACADIA Pharmaceuticals (1) Sherief Abd-Elsalam (1) NSC-Therapeutics (1)

Related targets

CHRM3 (9) CHRM2 (5) CHRM4 (3) SIGMAR1 (1) HTR1A (1) SLC6A2 (1) CHRM5 (1)

Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.